Bioceres (BIOX) CFO Simmermacher Receives Stock Award

What Happened

• Ezequiel Simmermacher, Chief Financial Officer of Bioceres Crop Solutions Corp. (BIOX), received a grant of 375,000 equity awards on August 3, 2026. The Form 4 records the transaction as an award/acquisition (code A) of a derivative instrument at $0.00 (reported value $0 on the form), i.e., a stock option/award rather than an open-market purchase.

Key Details

• Transaction date: August 3, 2026; filing date: August 4, 2026 (Form 4 accession 0001104659-26-090273).
• Reported price on Form 4: $0.00 (derivative award); reported aggregate dollar amount: $0 (award/grant reported, not a cash transaction).
• Shares/options granted: 375,000.
• Shares owned after transaction: Not specified in the excerpt provided.
• Footnote: The options were granted under the 2023 Omnibus Equity Incentive Plan and vest annually in three equal installments commencing June 30, 2026, subject to vesting conditions (see footnote F1).
• Filing timeliness: No indication of a late filing in the provided record (filed the day after the transaction; Form 4s are typically due within 2 business days).

Context

• This filing documents a derivative award (stock options) — not an exercised option or open-market trade. The $0.00 in the filing reflects the nature of the grant reporting, not market value; any future value depends on vesting and the company’s stock price.
• Grants like this are commonly used as employee compensation and do not, by themselves, indicate insider buying or selling intent.